Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122259 | 1.00 | TMEM97 (0.48) | TMEM97KMT2AGAAHSD17B10ATM | |
| SCHEMBL13016803 | 0.87 | TMEM97 (0.44) | TMEM97KMT2AGAAATMEGLN2 | |
| SCHEMBL3118589 | 0.87 | TMEM97 (0.44) | TMEM97KMT2AGAAATMEGLN2 | |
| SCHEMBL13016818 | 0.86 | TMEM97 (0.39) | TMEM97RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3104786 | 0.86 | TMEM97 (0.39) | TMEM97RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3109578 | 0.84 | EGLN2 (0.40) | TMEM97KMT2AEGLN2EGLN1RAB9A | |
| SCHEMBL13016821 | 0.84 | EGLN2 (0.40) | TMEM97KMT2AEGLN2EGLN1RAB9A | |
| SCHEMBL3111586 | 0.80 | EGLN2 (0.42) | GAAHSD17B10EGLN2EGLN1RAB9A | |
| SCHEMBL13016806 | 0.80 | EGLN2 (0.42) | GAAHSD17B10EGLN2EGLN1RAB9A | |
| SCHEMBL3104775 | 0.79 | TMEM97 (0.38) | TMEM97RAB9AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7642289-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | TMEM97 555/4885KMT2A 1080/4885GAA 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.